Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.
27 February 2015 | Chicago Tribune
The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.
25 February 2015 | EATG
U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.
24 February 2015 | Reuters
The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.
19 February 2015 | amfAR
With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.
18 February 2015 | Huffington Post
PatientView surveyed 1,150 patient groups from 58 countries and asked them about the corporate reputation of 37 pharma companies. The respondents ranked ViiV Healthcare number one across the board. Gilead fell from the #2 ranking position in 2013 to #14 in 2014—likely a consequence of the controversially high prices for specialty hep C meds.
16 February 2015 | Bio Pharma Dive
Earlier this week, PatientView published the results of its country survey, which asked more than 1,000 global patient groups to rank biopharmaceutical companies based on their overall "corporate reputation." For the second year in a row, ViiV Healthcare, a joint venture between Pfizer, GlaxoSmithKline, and Shionogi and headquartered in the U.K. (which may also have the biggest IPO for a pharma company ever later this year), emerged as number one.
16 February 2015 | BioPharma Dive
The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.
13 February 2015 | Financial Times
The big biotech tells FierceBiotech in a statement that the agency has "informed Bristol-Myers Squibb that, due to the evolving HCV treatment landscape, the agency intends to rescind the breakthrough therapy designation for certain genotype 1 hepatitis C regimens related to daclatasvir." Bristol-Myers then went on to add that the decision will not impact its timetable on an NDA for daclatasvir, which faces a unique set of challenges all its own.
11 February 2015 | Fierce Biotech
The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.
11 February 2015 | The Body Pro